Treatment Option For Amyloidosis
VYNDAMAX® (tafamidis) can help those living with ATTR-CM live longer with fewer heart-related hospital visits
At month 30 in a clinical trial of people with either wild-type or hereditary ATTR-CM, VYNDAMAX was proven to significantly reduce death and the number of heart-related hospitalizations in patients with ATTR-CM compared to those who did not take VYNDAMAX (placebo group).
The clinical studies of VYNDAQEL® (tafamidis meglumine) supported the approval of VYNDAMAX, which contains the same active ingredient.
VYNDAMAX helped more people live longer
Survival rate at month 30
In a clinical trial, VYNDAMAX was proven to significantly reduce death and the number of heart-related hospitalizations in patients with ATTR-CM. Patients in the VYNDAMAX group lived longer than those in the placebo group.
People who took VYNDAMAX had fewer heart-related hospitalizations
VYNDAMAX was proven to lower the risk of heart-related hospitalizations by 32% compared with placebo.
Keep in mind
It’s important to remember that even if you don’t feel VYNDAMAX working, always tell your doctor how you are feeling. Be reassured that VYNDAMAX has been proven to help adults with ATTR-CM live longer with fewer heart-related hospitalizations.
How was health-related quality of life measured in patients taking VYNDAMAX?
The Kansas City Cardiomyopathy Questionnaire
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-question survey that evaluates health-related quality of life. In the same clinical trial, people on VYNDAMAX scored better on a number of health measures at month 30 compared with those not taking VYNDAMAX (placebo group).*
∗Patients in the VYNDAMAX and placebo groups had worse KCCQ overall summary scores at month 30 than at the start of the study.